Get the Stockscreener App
5.01
2.91%
-0.15
After Hours:
5.00
-0.010
-0.20%
Ardelyx Inc stock is traded at $5.01, with a volume of 5.76M.
It is down -2.91% in the last 24 hours and up +7.51% over the past month.
Ardelyx Inc is a biotechnology company focused on the discovery, development, and commercialization of innovative, first-in-class medicines that meet significant unmet medical needs. The company has a proprietary drug discovery and design platform. Its lead product candidate is tenapanor, which aims to reduce the absorption of dietary sodium and phosphorus for the treatment of kidney disease, irritable bowel syndrome with constipation, and hyperphosphatemia in patients with dialysis.
See More
Previous Close:
$5.16
Open:
$5.2
24h Volume:
5.76M
Relative Volume:
1.26
Market Cap:
$1.19B
Revenue:
$251.85M
Net Income/Loss:
$-72.58M
P/E Ratio:
-15.99
EPS:
-0.3134
Net Cash Flow:
$-63.80M
1W Performance:
-1.18%
1M Performance:
+7.51%
6M Performance:
-12.87%
1Y Performance:
-41.20%
1-Day Range:
$5.00
$5.29
1-Week Range:
$4.98
$6.07
52-Week Range:
$4.32
$10.13
Ardelyx Inc Stock (ARDX) Company Profile
Name
Ardelyx Inc
Sector
Industry
Phone
510-745-7047
Address
34175 ARDENWOOD BLVD., FREMONT, CA
Compare ARDX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARDX
Ardelyx Inc
|
5.01 | 1.19B | 251.85M | -72.58M | -63.80M | -0.3134 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
Ardelyx Inc Stock (ARDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-11-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jul-02-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Apr-05-24 | Initiated | Leerink Partners | Outperform |
| Dec-18-23 | Initiated | Raymond James | Strong Buy |
| Sep-07-23 | Initiated | H.C. Wainwright | Buy |
| Aug-25-23 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Mar-03-23 | Upgrade | Wedbush | Neutral → Outperform |
| Nov-17-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| May-06-22 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Dec-01-21 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Oct-14-21 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Jul-21-21 | Downgrade | Jefferies | Buy → Hold |
| Jul-20-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-20-21 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-23-21 | Initiated | Wedbush | Outperform |
| Jan-06-21 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-20-20 | Resumed | Citigroup | Buy |
| Feb-18-20 | Resumed | Jefferies | Buy |
| Feb-12-20 | Initiated | Citigroup | Buy |
| Feb-10-20 | Initiated | Cowen | Outperform |
| Apr-08-19 | Initiated | Piper Jaffray | Overweight |
| Aug-24-18 | Initiated | Jefferies | Buy |
| Mar-19-18 | Resumed | Leerink Partners | Outperform |
| Nov-29-17 | Reiterated | Citigroup | Buy |
| Nov-22-17 | Reiterated | Ladenburg Thalmann | Buy |
| Oct-17-17 | Resumed | Leerink Partners | Outperform |
| Mar-31-16 | Initiated | Ladenburg Thalmann | Buy |
| Mar-09-16 | Initiated | Cantor Fitzgerald | Buy |
| Mar-03-16 | Initiated | Citigroup | Buy |
View All
Ardelyx Inc Stock (ARDX) Latest News
Recent 15% pullback isn't enough to hurt long-term Ardelyx (NASDAQ:ARDX) shareholders, they're still up 504% over 3 years - Simply Wall St
Ardelyx (NASDAQ:ARDX) Earns Neutral Rating from HC Wainwright - MarketBeat
Ardelyx, Inc. (NASDAQ:ARDX) Shares Purchased by Hennion & Walsh Asset Management Inc. - MarketBeat
Ardelyx (NASDAQ:ARDX) Shares Up 8.3%Still a Buy? - MarketBeat
Ardelyx (NASDAQ:ARDX) Stock Price Down 3.7%Time to Sell? - MarketBeat
Ardelyx (ARDX) Moves 16.0% Higher: Will This Strength Last? - MSN
Ardelyx (NASDAQ:ARDX) Stock Price Up 8.3%What's Next? - MarketBeat
Ardelyx's Ibsrela sales beat expectations, shares surge By Investing.com - Investing.com Canada
Ardelyx reports strong 2024 sales, eyes growth in 2025 By Investing.com - Investing.com Canada
Ardelyx provides update on commercial progress; shares up 8% - MSN
Ardelyx reports strong 2024 sales, eyes growth in 2025 - Investing.com
Ardelyx Provides Update on Increasing Commercial Momentum and 2025 Strategic Priorities - The Manila Times
Ardelyx Reports Strong 2024: IBSRELA, XPHOZAH Drive $319M Revenue as Growth Accelerates - StockTitan
Ardelyx CEO Michael Raab sells $221k in stock - Investing.com India
Ardelyx CEO Michael Raab sells $221k in stock By Investing.com - Investing.com Australia
Ardelyx, Inc. (NASDAQ:ARDX) CEO Michael Raab Sells 41,666 Shares - MarketBeat
Ardelyx (NASDAQ:ARDX) Shares Up 5.8%Should You Buy? - MarketBeat
Ardelyx to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Ardelyx CEO to Present at JP Morgan Healthcare Conference 2025 in San Francisco - StockTitan
Ardelyx, Inc. (NASDAQ:ARDX) Receives $10.07 Average PT from Brokerages - MarketBeat
Principal Financial Group Inc. Has $933,000 Stock Holdings in Ardelyx, Inc. (NASDAQ:ARDX) - MarketBeat
Beyond The Numbers: 4 Analysts Discuss Ardelyx Stock - Benzinga
Jefferies Financial Group Issues Pessimistic Forecast for Ardelyx (NASDAQ:ARDX) Stock Price - MarketBeat
(ARDX) Investment Analysis - Stock Traders Daily
Ardelyx (NASDAQ:ARDX) Stock Price Down 3.8%Here's Why - MarketBeat
Why Ardelyx (ARDX) Is One of the Best Biotech Penny Stocks to Invest in Now? - Insider Monkey
Exploring 3 High Growth Tech Stocks in the United States - Simply Wall St
Lost Money on Ardelyx, Inc.(ARDX)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - The Eastern Progress Online
Ardelyx (NASDAQ:ARDX) Stock Price Up 4.6%What's Next? - MarketBeat
US Penny Stocks To Watch In December 2024 - Simply Wall St
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates C - GuruFocus.com
Ardelyx (NASDAQ:ARDX) Shares Gap Up After Insider Buying Activity - MarketBeat
Ardelyx, Inc. (NASDAQ:ARDX) Director David M. Mott Purchases 213,300 Shares - MarketBeat
Ardelyx director David Mott buys $996,580 in stock By Investing.com - Investing.com Nigeria
Ardelyx director David Mott buys $996,580 in stock - Investing.com
Ardelyx, Inc. (NASDAQ:ARDX) Shares Bought by Barclays PLC - MarketBeat
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ardelyx - The Eastern Progress Online
Ardelyx: A Small Bet Its Latest Setback Will Be Temporary (NASDAQ:ARDX) - Seeking Alpha
Ardelyx stock hits 52-week low at $4.34 amid market challenges - Investing.com Canada
Ardelyx Inc Stock (ARDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.65%
4.62%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):